When investigating patterns of copy-number alterations in lung adenocarcinomas, with respect to KRAS mutation status and after adjustment for a cohort effect, our proposed strategy highlights two subgroups of pure or nearly pure wild-type KRAS tumors. This evidence concerns the gene KRAS and lung adenocarcinoma.